Hawaii Minority Health and Cancer Disparities SPORE

夏威夷少数民族健康与癌症差异 SPORE

• 批准号: 10716152
• 负责人: Jeffrey Lee Berenberg
• 金额: $ 167.32万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-19 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10716152
• 关键词: Address; Adenocarcinoma; Adherence; Asian Americans; Behavioral; Bioinformatics; Biological; Biological Markers; Biometry; Blood specimen; Breast; Breast Cancer Risk Factor; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Prognosis; Catchment Area; Cells; Center for Translational Science Activities; Central obesity; Characteristics; Clinical; Clinical Management; Collaborations; Communities; Community Clinical Oncology Program; DNA Methylation; Data Analyses; Data Science; Development; Dietary Practices; Disease; Economics; Environment; Ethnic Population; Etiology; Evaluation; Fatty acid glycerol esters; Freezing; Funding; Future; Goals; Grant; Hawaii; Image; Individual; Infrastructure; Institution; Intervention; Intervention Studies; Leukocytes; Liver; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Mammary Neoplasms; Measures; Methylation; Minority; Minority Groups; Minority Health Research; Molecular; Mutation; Native Hawaiian; Native Hawaiian or Other Pacific Islander; Not Hispanic or Latino; Obesity; Outcome; Pacific Islands; Pathology; Patients; Performance; Phase; Pilot Projects; Population; Population Group; Population Heterogeneity; Prevention; Primary carcinoma of the liver cells; Randomized; Research; Research Infrastructure; Research Personnel; Rest; Risk; Small Cell Carcinoma; Smoker; Specialized Program of Research Excellence; Squamous Cell; Strategic Planning; Testing; Therapeutic; Translating; Translational Research; Translations; Tumor Biology; Universities; Visceral; Vulnerable Populations; biobank; cancer health disparity; cancer risk; career; chronic liver disease; community based participatory research; community center; data management; efficacy testing; elastography; ethnic difference; ethnic disparity; experience; follow-up; health care quality; health disparity; health equity; improved; innovation; lifestyle intervention; lung cancer screening; malignant breast neoplasm; minority health disparity; multi-ethnic; multidisciplinary; non-alcoholic fatty liver; non-alcoholic fatty liver disease; outreach; phase III trial; pilot trial; prediction algorithm; prognostic significance; programs; racial difference; racial disparity; radiomics; randomized trial; recruit; risk prediction model; screening; screening guidelines; secondary endpoint; social culture; tool; transcriptomics; translational study; tumor; tumor microenvironment; underserved minority; uptake

Project Summary/Abstract At the root of health disparities is the diversity that exists in the biological, behavioral, sociocultural, and environmental characteristics of individuals and populations. Hawai`i offers exceptional opportunities for minority health research due to its uniquely diverse population with varying cancer burdens and its high-quality health care and cancer registration. The University of Hawai`i Cancer Center has a successful track record of leveraging Hawai`i's multiethnic population to study racial/ethnic differences in cancer risk and outcomes. It has built a community-facing infrastructure to translate these findings into major biological discoveries and clinical innovations that would help to alleviate cancer disparities in the US. We propose in this P50 (PAR-20-305) to establish a SPORE program to conduct translational research focusing on Asians Americans, Native Hawaiians and Pacific Islanders (AANHPI), the fastest growing US minority, to initially address three cancers of particularly high relevance. Project 1 will address the high rates of hepatocellular carcinoma (HCC) in this population by implementing a randomized lifestyle intervention among AANHPI patients with non-alcoholic fatty liver (NAFLD) and by investigating mechanistic biomarkers (cell-free and leukocyte DNA methylation) that may also provide much needed clinical management tools. We will test the efficacy of intermittent vs. continuous energy restriction to reverse the progression of NAFLD in AANHPI, the most common etiology of chronic liver disease and liver cancer in this population. Project 2 will address the excess lung cancer burden experienced by Native Hawaiians by developing a risk-based and culturally-informed lung cancer screening strategy, and investigate the mutation, methylation and transcriptomic profiles of lung squamous cell and small cell carcinomas and adenocarcinomas that contribute to the unexplained poor survival in this vulnerable population. Project 3 will address the very high breast cancer burden of Native Hawaiians and the rising rates in Asian Americans by testing the adequacy of current radiomic risk prediction algorithms for predicting breast cancer in these populations and by investigating related molecular and histopathologic features of breast tumor environment which may be related to visceral adiposity and have prognostic significance. We will also establish: 1) an Administrative Core with strategic planning, advisory and evaluation components; 2) an Outreach and Recruitment Core (ORC) facilitating studies among minorities; 3) a centralized biorepository of paired fresh-frozen tumor and blood samples, as well as archival tumor blocks (Pathology & Biospecimen Core); 4) a Biostatistics & Bioinformatics Core; 5) a Developmental Research Program to fund innovative pilot studies and a Career Enhancement Program to support promising investigators new to translational research; and 6) new collaborations, with other institutions for the further translation of our findings. The successful completion of this grant will significantly advance our ability to reduce the high burden of liver, lung and breast cancers in AANHPI and to conduct other innovative translational minority health research that will benefit Hawai`i, the Pacific region and the rest of the US.

项目摘要/摘要 健康差异的根源是生物学，行为，社会文化和 个人和人群的环境特征。夏威夷为少数族裔提供了特殊的机会 健康研究由于其独特的人口多样化，癌症负担不同及其高质量的健康 护理和癌症注册。夏威夷大学癌症中心有成功的记录 夏威夷人的多种族人口研究癌症风险和结果的种族/种族差异。它已经建立了 面向社区的基础设施将这些发现转化为主要的生物学发现和临床 有助于减轻美国癌症差异的创新。我们在此P50（Par-20-305）中提出了 建立一个孢子计划，进行转化研究，重点是亚洲人美国人，夏威夷原住民 和太平洋岛民（Aanhpi），这是美国增长最快的美国少数派，最初针对三种癌症 高相关性。项目1将解决该人群中肝细胞癌（HCC）的高率 在非酒精脂肪肝（NAFLD）的AANHPI患者中实施随机生活方式干预 并研究机械生物标志物（无细胞和白细胞DNA甲基化），也可能提供 急需的临床管理工具。我们将测试间歇性与连续能量限制的功效 为了扭转AANHPI中NAFLD的发展，慢性肝病和肝脏最常见的病因 该人群中的癌症。项目2将解决夏威夷本地人经历的多余的肺癌负担 通过制定一种基于风险的和文化的肺癌筛查策略，并研究突变， 肺鳞状细胞和小细胞癌和腺癌的甲基化和转录谱 这有助于在这个脆弱的人群中无法解释的生存不佳。项目3将解决很高的问题 夏威夷原住民的乳腺癌负担和亚裔美国人的率上升，通过测试适当的 当前用于预测这些人群乳腺癌并通过研究 乳腺肿瘤环境的相关分子和组织病理学特征，可能与内脏有关 肥胖，具有预后意义。我们还将建立：1）具有战略性的行政核心 计划，咨询和评估组件； 2）促进的外展和招聘核心（ORC） 少数民族的研究； 3）配对的新鲜冻结肿瘤和血液样本的集中式生物座 作为档案肿瘤阻滞（病理与生物循环核心）； 4）生物统计学和生物信息学核心； 5）a 发展研究计划，以资助创新的试点研究和职业增强计划 支持新手转化研究的有前途的调查员； 6）与其他机构的新合作 为了进一步翻译我们的发现。这笔赠款的成功完成将大大推动我们的 能够减轻AANHPI中肝，肺和乳腺癌的高负担并进行其他创新 转化少数民族健康研究将使夏威夷，太平洋地区和美国其他地区受益。